Citigroup’s Legend Biotech LEGN Stock Holding History

Citigroup’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-72,000	Closed	-$2.08M	–	6163
2026 Q2	$2.08M	Buy	72,000 +42,000	+140%	+$1.13M	﹤0.01%	2901
2026 Q1	$543K	Hold	30,000	–	–	﹤0.01%	3504
2025 Q4	$652K	Buy	30,000 +15,000	+100%	+$430K	﹤0.01%	3421
2025 Q3	$489K	Sell	15,000 -15,000	-50%	-$554K	﹤0.01%	3592
2025 Q2	$1.06M	Sell	30,000 -56,400	-65%	-$1.83M	﹤0.01%	3156
2025 Q1	$2.93M	Buy	86,400 +56,400	+188%	+$2.02M	﹤0.01%	2371
2024 Q4	$976K	Buy	+30,000	New	+$1.24M	﹤0.01%	3390
2023 Q4	–	Sell	-24,900	Closed	-$1.67M	–	5794
2023 Q3	$1.67M	Buy	+24,900	New	+$1.73M	﹤0.01%	2114
2023 Q2	–	Sell	-29,800	Closed	-$1.44M	–	5659
2023 Q1	$1.44M	Buy	+29,800	New	+$1.46M	﹤0.01%	2258
2022 Q4	–	Sell	-29,800	Closed	-$1.22M	–	5865
2022 Q3	$1.22M	Buy	+29,800	New	+$1.4M	﹤0.01%	2563
2022 Q2	–	Sell	-20,000	Closed	-$727K	–	6463
2022 Q1	$727K	Buy	+20,000	New	+$790K	﹤0.01%	3229

Other funds holding LEGN

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

NLB Skladi upravljanje premozenja Ljubljana $2.71B AUM 53.8% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Citigroup's LEGN Position: Q3 2026 in Review

Citigroup increased its Legend Biotech (LEGN) stake by 35% in Q3 2026, buying an estimated $419K and bringing the position to 75,885 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3028.

Citigroup first reported a position in LEGN in Q4 2020 and has held it in 24 quarters since. The position peaked at $6.29M in Q2 2022. 50 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

Citigroup held 75,885 shares of Legend Biotech worth $1.51M as of Q3 2026.
Citigroup bought 19,638 Legend Biotech shares in Q3 2026, an estimated $419K.
Legend Biotech made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3028 holding.
Citigroup first reported a position in Legend Biotech in Q4 2020 and has held it in 24 quarters since.
Citigroup's Legend Biotech position peaked at $6.29M in Q2 2022.
50 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.